- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
- Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
- Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
- Cullinan Oncology to Participate in Upcoming Investor Conferences
- Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
More ▼
Key statistics
On Friday, Cullinan Therapeutics Inc (CGEM:NSQ) closed at 23.81, -21.13% below its 52-week high of 30.19, set on May 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.76 |
---|---|
High | 24.27 |
Low | 22.75 |
Bid | 22.00 |
Offer | 23.47 |
Previous close | 23.81 |
Average volume | 824.97k |
---|---|
Shares outstanding | 57.63m |
Free float | 54.88m |
P/E (TTM) | -- |
Market cap | 1.34bn USD |
EPS (TTM) | -3.70 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼